<DOC>
	<DOCNO>NCT01831765</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial investigate efficacy safety FIAsp ( faster-acting insulin aspart ) compare insulin aspart , combination insulin detemir adult type 1 diabetes . This trial consist two period : 26 week treatment period follow 26 week additional treatment period .</brief_summary>
	<brief_title>Efficacy Safety FIAsp Compared Insulin Aspart Both Combination With Insulin Detemir Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes ( diagnose clinically ) 12 month long time screen ( Visit 1 ) Currently treat basalbolus insulin regimen least 12 month prior screen ( Visit 1 ) Currently treat basal insulin analogue ( regimen insulin detemir insulin glargine ) least 4 month prior screen ( Visit 1 ) HbA1c 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) assess central laboratory Body Mass Index ( BMI ) equal 35.0 kg/m^2 Use antidiabetic drug insulin within last 3 month prior screen ( Visit 1 ) Recurrent severe hypoglycaemia ( one severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator , hospitalisation diabetic ketoacidosis previous 6 month prior screen ( Visit 1 ) Cardiovascular disease , within last 6 month prior screen ( Visit 1 ) , define stroke , decompensated heart failure New York Heart Association ( NYHA ) class III IV , myocardial infarction , unstable angina pectoris , coronary arterial bypass graft angioplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>